Holen Sie sich die Stockscreener-App
6.82
0.29%
0.02
Handel nachbörslich:
6.86
0.04
+0.59%
Schlusskurs vom Vortag:
$6.80
Offen:
$6.79
24-Stunden-Volumen:
301.42K
Relative Volume:
0.68
Marktkapitalisierung:
$343.67M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
11.18
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
-1.73%
1M Leistung:
+9.29%
6M Leistung:
+28.68%
1J Leistung:
+134.36%
1-Tages-Spanne:
$6.70
$6.99
1-Wochen-Bereich:
$6.37
$6.99
52-Wochen-Spanne:
$2.575
$7.285
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
6.82 | 342.66M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Re - pharmiweb.com
Puma Biotechnology sets Feb. 26 call on 2025 financial results - Stock Titan
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Will Puma Biotechnology Inc. stock maintain dividend yieldJuly 2025 Opening Moves & Capital Efficiency Focused Strategies - mfd.ru
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Why Puma Biotechnology Inc. stock is popular among millennials2025 Volume Leaders & Risk Controlled Daily Trade Plans - mfd.ru
Fund Flows: Is Puma Biotechnology Inc undervalued by DCF analysisTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2026 - BioSpace
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule - TradingView
Puma Biotechnology (PBYI) Price Target Increased by 42.86% to 5.10 - Nasdaq
Investor Mood: How does Puma Biotechnology Inc. compare to its peersRisk Management & Risk Controlled Stock Alerts - baoquankhu1.vn
Published on: 2026-02-03 15:38:46 - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Buys 159,200 Shares of Puma Biotechnology, Inc. $PBYI - MarketBeat
Revenue Check: Is Puma Biotechnology Inc. stock suitable for long term investing - mfd.ru
Hedge Fund Bets: Is FONAR Corporation exposed to currency risks2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Surprises Report: Will Puma Biotechnology Inc benefit from rate cutsJuly 2025 Action & Verified Short-Term Plans - baoquankhu1.vn
Momentum Shift: Can CALC maintain sales growthEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand – Company AnnouncementFT.com - Financial Times
New Thai breast cancer drug helps HER2+ patients lower relapse risk - Stock Titan
Sentiment Review: How does Puma Biotechnology Inc compare to its peers2025 Institutional Moves & Safe Capital Growth Plans - baoquankhu1.vn
Zacks Research Issues Pessimistic Forecast for PBYI Earnings - MarketBeat
Ritholtz Wealth Management Raises Stake in Puma Biotechnology, Inc. $PBYI - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
EPS Watch: How Puma Biotechnology Inc stock valuations compare to rivalsWeekly Stock Analysis & High Accuracy Trade Signal Alerts - Bộ Nội Vụ
Death Cross: Can Puma Biotechnology Inc stock beat analyst upgradesJuly 2025 Big Picture & High Accuracy Investment Signals - Bộ Nội Vụ
Investing in Puma Biotechnology (NASDAQ:PBYI) a year ago would have delivered you a 103% gain - Yahoo Finance
Investor Mood: What dividend safety score for Puma Biotechnology Inc. stock2025 Market Outlook & Weekly Watchlist of Top Performers - Bộ Nội Vụ
Hunt Douglas, SVP at Puma Biotechnology, sells $52,695 in PBYI By Investing.com - Investing.com UK
Will Puma Biotechnology Inc. stock keep outperforming rivalsTrade Risk Report & AI Enhanced Execution Alerts - Улправда
Puma Biotechnology (NASDAQ:PBYI) CEO Sells $105,910.56 in Stock - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Insider Douglas Hunt Sells 3,973 Shares - MarketBeat
Puma biotech CFO Nougues sells $64k in shares By Investing.com - Investing.com Australia
Auerbach Alan sells Puma Biotechnology (PBYI) shares worth $204k By Investing.com - Investing.com Australia
Hunt Douglas, SVP at Puma Biotechnology, sells $52,695 in PBYI - Investing.com
Puma biotech CFO Nougues sells $64k in shares - Investing.com
Auerbach Alan sells Puma Biotechnology (PBYI) shares worth $204k - Investing.com
Will Puma Biotechnology Inc. stock continue dividend increasesEarnings Trend Report & Reliable Price Breakout Signals - Улправда
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Puma Biotechnology Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - sharewise.com
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) - BioSpace
Puma Biotechnology Added to Nasdaq Biotechnology Index - marketscreener.com
If EPS Growth Is Important To You, Puma Biotechnology (NASDAQ:PBYI) Presents An Opportunity - Yahoo Finance
How Puma Biotechnology Inc. stock reacts to oil pricesPortfolio Value Report & Low Risk High Reward Trade Ideas - Улправда
What dividend safety score for Puma Biotechnology Inc. stockJuly 2025 Momentum & Long-Term Growth Portfolio Plans - Улправда
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AUERBACH ALAN H | President and CEO |
Jan 06 '26 |
Sale |
5.84 |
16,938 |
98,986 |
7,163,963 |
| HUNT DOUGLAS M | See Remarks |
Jan 07 '26 |
Sale |
5.88 |
5,014 |
29,477 |
155,907 |
| HUNT DOUGLAS M | See Remarks |
Jan 06 '26 |
Sale |
5.84 |
3,973 |
23,218 |
160,921 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 07 '26 |
Sale |
5.88 |
6,405 |
37,655 |
193,284 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 06 '26 |
Sale |
5.84 |
4,540 |
26,532 |
199,689 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):